Cervical cancer is the most serious consequence of infection by human papillomavirus (HPV), constituting one of the leading causes of death among women worldwide, and a fact that points to a major challenge to global public health. The prophylactic vaccination on a large scale would be an alternative to reducing cervical cancer rates, making it essential to search for new vaccine strategies. Current vaccines are based on virus-like particles (VLPs) of the major virus capsid protein L1, with effective protection against specific types, but with a limited cross-protection against other HPV types. The vaccine proposal is to use the L2 protein, which contains highly conserved sequences for a broader protection against different types of HPVs.
INTRODUCTION
Cervical cancer is the most serious consequence of infection by human papillomavirus (HPV), constituting one of the leading causes of death among women worldwide, and a fact that points to a major challenge to global public health. The prophylactic vaccination on a large scale would be an alternative to reducing cervical cancer rates, making it essential to search for new vaccine strategies. Current vaccines are based on virus-like particles (VLPs) of the major virus capsid protein L1, with effective protection against specific types, but with a limited cross-protection against other HPV types. The vaccine proposal is to use the L2 protein, which contains highly conserved sequences for a broader protection against different types of HPVs.
OBJECTIVE In this study, we have developed the production of VLPs containing L1 and L2 recombinant proteins of HPV16, using human embryonic kidney cells (293-F) suspended in medium fetal bovine serum free.
METHODOLOGY Cells 293-F were cultivated in serum-free medium and cotransfected with expression vectors for mammals pUF3L1 (L1) and pU3L2h (L2). The expression of the proteins L1 and L2 were analyzed by confocal laser microscopy, flow cytometry and transmission electron microscopy. The recombinant proteins HPV16L1L2 were purifiedby affinity chromatography with heparin resin and immunized in Balb/c mice subcutaneously with three doses of HPV16L1L2 formulated with aluminum hydroxide as an adjuvant and used saline solution as control. The immune response induced by recombinant HPV16L1L2 was evaluated by Elisa test and western-blotting.
RESULTS
The kinetics of expression of the HPV16 proteins L1L2 showed that maximal expression occurs around 48h post-transfection by confocal microscopy and flow cytometry. Both proteins were localized in the nucleus and cytoplasm of cells. The analysis by transmission electron microscopy showed the formation of VLPs and the presence of proteins L1 and L2 through colloidal gold immunolabeling, in cell lysate. Purification by affinity chromatography allows obtaining VLPs more structurally correct. The immunoassays by Western blotting and ELISA confirmed the induction of immune response to both proteins by the immune system of mice. The serum anti-HPV16 L1 and anti-HPV16 L2 of animals immunized with VLPs L1L2 recognized the major protein L1 molecular weight around 55 kDa and the secondary protein L2 of approximately 72 kDa, respectively. The ELISA assays demonstrated that serum antibodies showed anti-HPV16 L1 titers above in relation to anti-HPV16 L2 in the group immunized with adjuvant.
